Combining radiotherapy with gene therapy (from the bench to the bedside): a novel treatment strategy for prostate cancer.
Bin S Teh, Estuardo Aguilar-Cordova, Maria T Vlachaki...
https://pubmed.ncbi.nlm.nih.gov/12401909/Actively Recruiting
Led by The Methodist Hospital Research Institute · Updated on 2021-04-06
60
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating the safety and effectiveness of a gene therapy called HSV-tk combined with valacyclovir, alongside androgen deprivation therapy, brachytherapy, external beam radiotherapy, and prostatectomy in men with previously untreated high-risk prostate cancer. This phase II study aims to understand how well this combination controls the disease and its side effects. Participants will receive the HSV-tk gene therapy injected into the prostate twice, on day 0 and day 30. Valacyclovir will be taken orally three times daily for two separate 14-day periods. They will also receive daily Bicalutamide tablets combined with monthly Leuprolide acetate injections for two months. Around day 60, participants will undergo high dose rate brachytherapy using needle catheters and radiation. Approximately 2 to 3 weeks after completing radiotherapy, patients will have a radical prostatectomy surgery. Throughout the study, participants will be closely monitored with blood tests, digital rectal exams, and prostate biopsies to assess cancer response and immune effects. Researchers will track prostate specific antigen PSA levels over time and watch for side effects using standardized scoring systems. The main outcome is the 5-year biochemical disease-free survival rate. Safety and overall survival will also be followed for up to five years after treatment.
CONDITIONS
Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery
E
Emily Hsiao, Ph.D.
C
Christine O'Reilly
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
The Methodist Hospital Research Institute
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Multi-modal regimen: gene therapy plus ADT, radiotherapy and radical prostatectomy | Guideline-based standard: androgen deprivation therapy plus radiotherapy ± brachytherapy, with or without planned radical prostatectomy |
|---|---|---|
| What it is | A stepwise experimental regimen combining direct intra-prostatic HSV-Tk gene therapy, antiviral drug (Valacyclovir), short-course androgen deprivation therapy (Bicalutamide and Leuprolide Acetate), followed by high-dose-rate brachytherapy, external beam radiotherapy, and finally radical prostatectomy for adults with high-risk localized prostate cancer. | Established standard of care for high-risk, localized prostate cancer consists of long-term androgen deprivation therapy (usually luteinizing hormone-releasing hormone agonists or antagonists, with or without oral antiandrogen), external beam radiotherapy (with or without brachytherapy boost), and in selected cases, planned or salvage radical prostatectomy. |
| Role in trial | Investigational treatment arm; all enrolled participants receive the full sequence of gene therapy, systemic therapy, radiation, and surgery under protocol supervision. | Not a part of this trial; represents options offered in routine care for similar patients according to best available evidence and clinical guidelines. |
| Primary use | To investigate the feasibility, safety, and 5-year disease control of a multimodal regimen that incorporates novel intra-prostatic gene therapy with systemic and local standard therapies in high-risk, non-metastatic prostate cancer. | To provide optimal disease control for high-risk, non-metastatic prostate cancer, usually aiming for cure or long-term control using a combination of hormonal and radiotherapy, sometimes combined with surgery. |
| How it is given or performed | Participants first receive HSV-Tk gene therapy by direct injection into the prostate, combined with oral Valacyclovir. This is followed by a short course of Bicalutamide and monthly Leuprolide Acetate injections for androgen deprivation, then high-dose-rate brachytherapy and external beam radiotherapy, and finally, radical prostatectomy performed 2–3 weeks after radiotherapy. | External beam radiotherapy is combined with long-term androgen deprivation therapy (usually for 2–3 years). Some guidelines recommend adding brachytherapy. Radical prostatectomy may be offered to selected patients, with the possibility of postoperative radiotherapy if adverse features are present. No gene therapy is used in standard practice. |
| Evidence status | Results are not yet established for this combination; HSV-Tk gene therapy regimens are in early-phase investigation for prostate cancer and have shown preliminary safety and feasibility but are not proven to improve long-term survival or disease control in randomized controlled trials. | Robust evidence, including randomized phase III trials, supports improved disease control and overall survival with long-term androgen deprivation therapy plus external beam radiotherapy, in some cases with brachytherapy boost or surgery for high-risk patients. |
| Important limitations | As a single-arm early-phase trial, this regimen’s long-term benefits and safety are unproven. Small sample size, complex multi-step process, and investigational nature of gene therapy (HSV-Tk) mean that efficacy and safety versus standard care remain uncertain. | Current standard therapies have known long-term side effects, including urinary, sexual, and bowel dysfunction, and recurrence remains possible in high-risk disease despite aggressive treatment. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Approximately 2 months
Participants receive HSV-tk gene therapy injections into the prostate on day 0 and day 30, and take oral valacyclovir twice daily for two 14-day periods. Hormone therapies with Bicalutamide tablets daily and monthly Leuprolide acetate injections are also given.
Duration - 1 day
Participants undergo high dose rate brachytherapy on day 60 using needle catheters and radiation planning for targeted treatment.
1 visit (in-person)
Duration - 1 day
About 2 to 3 weeks after completing radiation, participants have radical prostatectomy surgery with lymph node dissection.
1 visit (hospital stay)
Duration - Up to 5 years
Participants are monitored with regular blood tests, prostate exams, biopsies, and assessments for cancer control and side effects over several years.
Periodic visits for tests and check-ups
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Bin S Teh, Estuardo Aguilar-Cordova, Maria T Vlachaki...
https://pubmed.ncbi.nlm.nih.gov/12401909/Ofer Yossepowitch, Scott E Eggener, Fernando J Bianco...
https://pubmed.ncbi.nlm.nih.gov/17561152/Jacques Ferlay, Hai-Rim Shin, Freddie Bray...
https://pubmed.ncbi.nlm.nih.gov/21351269/Bin S Teh, Gustavo Ayala, Laura Aguilar...
https://pubmed.ncbi.nlm.nih.gov/15050332/James L Gulley, Philip M Arlen, Anne Bastian...
https://pubmed.ncbi.nlm.nih.gov/15867235/Guido Kroemer, Lorenzo Galluzzi, Oliver Kepp...
https://pubmed.ncbi.nlm.nih.gov/23157435/Juanita Crook, Charles Ludgate, Shawn Malone...
https://pubmed.ncbi.nlm.nih.gov/18707821/Svend O Freytag, Hans Stricker, Jan Pegg...
https://pubmed.ncbi.nlm.nih.gov/14612551/Svend O Freytag, Benjamin Movsas, Ibrahim Aref...
https://pubmed.ncbi.nlm.nih.gov/17375076/G K Zagars, A Pollack, V S Kavadi...
https://pubmed.ncbi.nlm.nih.gov/7538498/The Methodist Hospital Research Institute
Lead Sponsor